HBV-associated cryoglobulinemic vasculitis: Remission after antiviral therapy with entecavir

Mauro Viganò, Paul Martin, Mattia Cappelletti, Fabrizio Fabrizi

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background/Aims: Cryoglobulinemic vasculitis remains an uncommon complication of hepatitis B virus infection. Methods: We report the case of a 40-years old female Chinese patient with chronic hepatitis B developing cryoglobulinemic vasculitis with multiple organ involvement (liver, kidney, and skin) coupled with weakness, arthralgias, haemolytic anaemia, and autoimmune thyroiditis. She received entecavir mono-therapy at dose adjusted for estimated glomerular filtration rate. Results: Within five months of entecavir treatment, hepatitis B viraemia decreased below the limit of detection with normal serum amino-transferase levels, HBeAg clearance occurred, vasculitis regressed with disappearance of purpura and ascites; in addition, renal function normalized and nephritic syndrome remitted. After a five-year follow-up, the patient is asymptomatic with intact kidney function, proteinuria in the normal range, and normal liver biochemistry, despite the antiviral treatment was withdrawn and the patient remained HBsAg positive. Conclusions: This is the second case of hepatitis B virus-related cryoglobulinemic vasculitis successfully treated with entecavir suggesting that effective antiviral therapy may counteract both the hepatic and extra-hepatic manifestations of infection by hepatitis B virus.

Original languageEnglish
Pages (from-to)65-73
Number of pages9
JournalKidney and Blood Pressure Research
Issue number1
StatePublished - Jul 2014
Externally publishedYes


  • Antiviral therapy
  • Cryoglobulinemia
  • Entecavir
  • Hepatitis B virus
  • Vasculitis


Dive into the research topics of 'HBV-associated cryoglobulinemic vasculitis: Remission after antiviral therapy with entecavir'. Together they form a unique fingerprint.

Cite this